A class action against the NSW government and 15 local health districts alleging relatives of overseas patients were forced to serve as guarantors for hospital bills worth tens of thousands of dollars has settled.
Piper Alderman has resolved a sex discrimination case brought by a former administrative assistant who claimed she was terminated for taking parental leave and told to “go spend time with your kids”.
BlueScope Steel has raised concerns over the ACCC’s subpoenas to produce documents in its civil penalty proceedings against the steel company, saying it may significantly broaden the regulator’s claims about which businesses are its competitors.
The Australian arm of Fuchs Lubricants has succeeded in invalidating two patents owned by Quakers Chemicals, with the Full Federal Court finding the inventions were not novel because Quakers had tested them in public prior to applying for registration with IP Australia.
Just hours before her deadline, Australia Post’s board said Wednesday it would enter talks with ex-CEO Christine Holgate, but has asked that her demands be made public.
A mid-trial settlement has been reached in a lawsuit brought by the liquidators of collapsed steel giant Arrium against 10 former company directors and officers for allegedly engaging in insolvent trading.
A 73-year old Australian man has filed a constitutional challenge to the Morrison government’s decision to ban travel from India amid a devastating surge in coronavirus cases in the country.
The ACCC has secured a misuse of market power declaration against Tasmanian government-owned TasPorts in the regulator’s first action under amended competition laws, but the ports company will not pay a penalty as part of an agreement to resolve the case.
A shareholder class action against Crown Resorts can access transcripts of interviews conducted by the Victorian gaming regulator with former top brass and two Crown employees who were arrested in China in 2016 as part of a crackdown on gambling
Generic drug company Pharmacor has fired back in a patent lawsuit by Novartis, filing a cross-claim seeking to invalidate the Swiss drug giant’s patents for its blockbuster MS drug Gilenya.